Description
Innovative App to Prevent Prescription Deaths
Los Angeles, CA (Los Angeles County)
Seller Financing Available if the price and deal structure is right
Asking Price: $1,000,000
Cash Flow: $3,619
Gross Revenue: $9,710
EBITDA: N/A
FF&E: N/A
Inventory: N/A
Established: 2020
Employees: 3 plus contractors when required
Business Description
Our client has developed an innovative application and accompanying database aimed at addressing the third leading cause of death in the United States: adverse drug reactions due to inappropriate prescribing. This app is a unique tool that provides a second opinion on prescriptions, leveraging the expertise of 31 medical professionals who formulated the AGS Beers Criteria® and the STOPP/START® Criteria. Notably, this is the only platform that integrates both of these highly respected, globally recognized guidelines for safe and effective drug prescribing.
The potential market for this product is vast. In the U.S. alone, over 131 million people are prescribed medications, and many suffer severe consequences from incorrect prescriptions, leading to preventable fatalities and long-term hospitalizations. This issue isn’t limited to the U.S.; the app addresses a global need, positioning itself to rapidly expand its reach and impact on healthcare systems worldwide.
It is important to clarify that the app is not intended to diagnose conditions or prescribe medications based on symptoms. That responsibility remains with the patient’s healthcare provider. Instead, the app generates a detailed report based on the patient’s current prescriptions, which can be presented to their doctor as a second opinion. The report adheres to the exact terminology and recommendations validated and published by the experts. Patients are consistently informed that the report is intended solely for review by their healthcare provider, who retains the authority to interpret and act on the recommendations.
This tool is designed to empower patients with expert-backed insights while supporting prescribers in making the most informed decisions for their patients’ safety and well-being.
NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
Detailed Information
Facilities:
N/A
Competition:
First Mover in resolving ADE’s
Growth & Expansion:
Wants to continue expansion, growth is significant.
Financing:
Seller Financing Available if the price and deal structure is right
Support & Training:
As needed – specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business.
Reason for Selling:
Other business interests.
ProNova Partners Buyer Profile & NDA
***RED STARS ARE REQUIRED FIELDS***
This information is required and must be filled in completely before the Seller will release any vital information, including business address, financial due diligence package on file, and other sensitive confidential information.
It will also be used by ProNova Partners to match your buyer profile with future similar engagements our firm has for sale.
* Required
function validateCaptcha()
{
var web_set_captcha = 'No';
web_set_captcha = document.getElementById('web_set_captcha').value;
if(web_set_captcha == 'Yes')
{
var googleResponse = $('#g-recaptcha-response').val();
if (!googleResponse) {
$('
Please Validate Captcha.
').insertAfter("#captcha_element");
return false;
} else
return true;
}
else
return true;
}